Intellia Therapeutics Inc (NTLA)
21.85
+0.28
(+1.30%)
USD |
NASDAQ |
Apr 22, 16:00
21.83
-0.02
(-0.09%)
After-Hours: 20:00
Intellia Therapeutics Cash from Operations (Quarterly): -93.05M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -93.05M |
| September 30, 2023 | -101.38M |
| June 30, 2023 | -90.32M |
| March 31, 2023 | -109.33M |
| December 31, 2022 | -89.87M |
| September 30, 2022 | -78.53M |
| June 30, 2022 | -85.09M |
| March 31, 2022 | -79.80M |
| December 31, 2021 | -54.65M |
| September 30, 2021 | -65.02M |
| June 30, 2021 | -52.98M |
| March 31, 2021 | -52.38M |
| December 31, 2020 | -40.23M |
| September 30, 2020 | -28.56M |
| June 30, 2020 | 57.42M |
| March 31, 2020 | -38.54M |
| December 31, 2019 | -28.66M |
| September 30, 2019 | -25.45M |
| Date | Value |
|---|---|
| June 30, 2019 | -27.68M |
| March 31, 2019 | -21.45M |
| December 31, 2018 | -8.538M |
| September 30, 2018 | -12.45M |
| June 30, 2018 | -22.50M |
| March 31, 2018 | -17.77M |
| December 31, 2017 | -21.31M |
| September 30, 2017 | -16.89M |
| June 30, 2017 | -15.68M |
| March 31, 2017 | -11.40M |
| December 31, 2016 | -14.41M |
| September 30, 2016 | -7.61M |
| June 30, 2016 | 67.55M |
| March 31, 2016 | -9.421M |
| December 31, 2015 | -5.491M |
| September 30, 2015 | -3.267M |
| June 30, 2015 | 2.173M |
| March 31, 2015 | 4.822M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-109.33M
Minimum
Mar 2023
57.42M
Maximum
Jun 2020
-57.06M
Average
-54.65M
Median
Dec 2021
Cash from Operations (Quarterly) Benchmarks
| Moderna Inc | 622.00M |
| Regeneron Pharmaceuticals Inc | 1.090B |
| NeuroMetrix Inc | -1.450M |
| Repligen Corp | 29.06M |
| Pacific Biosciences of California Inc | -57.56M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 45.94M |
| Cash from Financing (Quarterly) | 106.48M |
| Free Cash Flow | -408.07M |
| Free Cash Flow Per Share (Quarterly) | -1.017 |
| Free Cash Flow to Equity (Quarterly) | -94.57M |
| Free Cash Flow Yield | -20.89% |